Zagazig University, Faculty of Pharmacy, Department of Analytical Chemistry, Zagazig 44519, Egypt.
Egyptian Russian University, Faculty of Pharmacy, Pharmaceutical Chemistry Department, Badr City, Cairo 11829, Egypt.
J AOAC Int. 2022 Dec 22;106(1):26-33. doi: 10.1093/jaoacint/qsac123.
Safinamide, a highly specific inhibitor of monoamine oxidase B, is a new approved prodigious therapy used to cure Parkinson's disease (PD).
Before marketing and selling a medicine, manufacturers must guarantee that the manufacturing process is consistent by monitoring levels of process-related chemicals and drug contaminants. Therefore, five precise, fast, and accurate spectrophotometric techniques were employed and evaluated for the simultaneous measurement of safinamide and its synthetic precursor, 4-hydroxybenzaldehyde.
The first derivative, derivative ratio, ratio difference, dual wavelength, and Fourier self-deconvolution methods worked well to resolve spectral overlap of safinamide and its synthetic precursor, 4-hydroxybenzaldehyde.
Safinamide detection limits ranged from 0.598 to 1.315 µg/mL, whereas the 4-hydroxybenzaldehyde detection limit was found to be as low as 0.327 µg/mL.
According to International Council for Harmonisation (ICH) criteria, all procedures were verified and confirmed to be accurate, robust, repeatable, and precise within reasonable range. No considerable variation was found when comparing the outcomes of the suggested approaches to the findings of previously published methods. The ecological value of established methods was measured: the national environmental methods index (NEMI), the analytical eco-scale, the analytical greenness metric (AGREE), and the green analytical process index (GAPI) were used.
This is the first spectrophotometric determination of safinamide drug in the presence of its synthetic precursor. Five simple and efficient spectrophotometric approaches were employed to determine a newly approved antiparkinsonian drug in the presence of its synthetic precursor simultaneously. Ecological appraisal was performed for the developed methods using four assessment tools.
氨苯酰沙明是一种高度特异性的单胺氧化酶 B 抑制剂,是一种新批准的治疗帕金森病(PD)的有效药物。
在销售药品之前,制造商必须通过监测与工艺相关的化学物质和药物污染物的水平,保证生产工艺的一致性。因此,采用了五种精确、快速、准确的分光光度技术,并对其进行了评估,以同时测定氨苯酰沙明及其合成前体 4-羟基苯甲醛。
一阶导数、导数比、比率差、双波长和傅里叶自解卷积法很好地解决了氨苯酰沙明及其合成前体 4-羟基苯甲醛的光谱重叠问题。
氨苯酰沙明的检测限范围为 0.598 至 1.315µg/mL,而 4-羟基苯甲醛的检测限低至 0.327µg/mL。
根据国际协调会议(ICH)标准,所有程序均经过验证和确认,在合理范围内准确、稳健、可重复且精确。与先前发表的方法相比,所建议方法的结果没有发现显著差异。建立方法的生态价值进行了测量:使用国家环境方法指数(NEMI)、分析生态标度、分析绿色度指标(AGREE)和绿色分析过程指数(GAPI)。
这是首次在存在其合成前体的情况下对氨苯酰沙明药物进行分光光度测定。采用五种简单高效的分光光度法,同时测定新批准的抗帕金森病药物及其合成前体。采用四种评价工具对所开发的方法进行了生态评估。